| Name | Title | Contact Details |
|---|
Cadence Neuroscience is developing a next generation implantable device therapy for epilepsy. The therapy, pioneered by researchers at Mayo Clinic over the past decade, uses advanced methods to provide individualized treatment for each patient. Our core technology includes a specialized neuromodulation platform that enables these methods. Cadence is currently engaged in the engineering and testing of the platform, and preparing for additional clinical evaluations.
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.
Encorium Group, Inc is a Berwyn, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential.
Solstice Neurosciences is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.